astellas

PATIENTS ARE WHY™
AN ASTELLAS PATIENT CENTRICITY PROGRAM

From Insights to Impact: Patient Partnerships That Make a Difference

Patient Engagement Annual Report 2025

MAT-GB-NON-2026-00106
June 2026

© 2026 Astellas Pharma Inc. or its affiliates. All trademarks are the property of their respective owners.
All photographs are shared with the consent of those featured.

Contents

Patient partnerships that make a difference

Foreword by Doug Noland, Global Head of Patient Partnerships, Shontelle Dodson, Global Head of Patient Centricity and four of our long-standing partners.



Global Head of Patient Partnerships
Doug Noland

Each year, this report is more than a reflection – it's a chance to pause, listen, and learn. Last year, we asked patient organizations for candid feedback, and we've done the same again because checking in matters. These conversations help us understand what's working, where we can do better, and how we can make a real difference together.

That difference doesn't happen in isolation. It's the result of joint working across many Astellas teams, bringing diverse expertise together alongside patient community input to turn feedback into meaningful action.

The theme of this year's report – **From Insights to Impact: Patient Partnerships That Make a Difference** – captures our approach. Insights from patients and caregivers aren't just words on a page; they shape decisions, spark innovation, and lead to solutions that improve outcomes for patients.

Looking ahead, we'll keep building on this approach, seeking feedback, deepening collaboration, and turning insights into impact. Because creating VALUE with patients, not just for them, is how we make healthcare more human.

We're proud to share the voices of four of our long-standing partners who offered their reflections about their experiences with Astellas and their ideas for how we can work together to make an even greater impact.

APS Associazione PaLiNUro, Italy
Edoardo Fiorini

Although healthcare and political systems aren't always designed to include patients in decision-making, since 2014 we've focused on driving change so people with bladder cancer can help shape their care.

For the past 5 years, Astellas has partnered with us on this journey. Together, we've worked with clinicians, payors, and policymakers to improve bladder cancer care in Italy and launched the **'Stop at Red'** campaign to raise awareness of early signs and symptoms, supporting timely diagnosis.

Our partnership shows how industry and patient communities can collaborate to create impact. Astellas seeks to understand and respond to real community needs, and the campaign remains central to our efforts, evolving to better support patients and doctors.

Change takes time, but through dialogue and trust, we can overcome system limitations and improve outcomes.



Macular Disease Foundation Australia, Australia
Dr Kathy Chapman

Building strong relationships between pharmaceutical companies and patient communities starts with reciprocity. If industry sees organizations like Macular Disease Foundation Australia (MDFA) only as sources of insights, it overlooks our mission. True reciprocity and collaboration mean working together to amplify reach, engagement, and impact.

It also requires long-term commitment. Macular disease is chronic, and patients' needs evolve. We seek partners who share our dedication to supporting people throughout their journey.

Our recent collaboration with Astellas on our **Eye Connect program** reflects this principle. Instead of overwhelming patients upfront, Eye Connect provides tailored resources, practical tools, and emotional support for specific moments in a patient's disease journey – such as diagnosis and treatment initiation – over 12 months.

Eye Connect shows how collaboration meets real needs and helps people adapt to vision loss. Together, we're helping people to live better with macular disease.



Women's Healthcare Awareness and Menopause Network Society, Japan
Yoshie Miwa

Menopause remains surrounded by misunderstanding, often preventing people from seeking proper medical care. By amplifying women's voices and sharing clear, evidence-based information, we can break down barriers, reduce stigma, and empower women to seek support.

Our work with Astellas has been pivotal. Through seminars and roundtable discussions, we've raised awareness of menopause, scientific advances in symptom management, and its impact on daily life.

Symptoms and needs vary greatly and change over time, so capturing lived experiences regularly is vital, as is bridging gaps between healthcare, government, and employers. Our shared goal is a society that values women's experiences, ensures access to solutions, and acknowledges how menopause shapes lives.



GI Cancers Alliance, US
Martha Raymond

Late diagnosis remains one of the greatest challenges in gastric cancer. We must work together to support timely detection and ensure people have access to treatment and support for the best chance at life.

Our partnership with Astellas reflects these principles. From patient-reported outcome research to emotional wellbeing resources and biomarker education, every project shows a shared commitment to understanding what matters most to patients and acting on it.

Collaboration rooted in respect and purpose creates real impact and gives people living with gastric cancer the best possible future. Driving change requires listening and acting. All voices matter and valuing patient communities as equal partners is the best way to make a difference.

Global Head of Patient Centricity, Astellas
Shontelle Dodson

It is a privilege to step into the role of Head of Patient Centricity at Astellas at a time when such strong foundations are already in place. Over recent years, our teams and patient partners have worked together to embed patient perspectives more deeply into how we think, decide, and act - and this report brings that progress to life.

What excites me most is not simply what we have achieved, but the momentum we have created. Across therapeutic areas and geographies, Astellas has shown what is possible when patient insights are genuinely valued - shaping research priorities, informing access and delivery, supporting quality of life, and challenging long standing barriers and stigma. These partnerships reflect a shared commitment to creating VALUE with patients, not just for them.

As we look ahead, my focus is on building on this strong foundation. Bringing consistency, clarity, and connection across our patient centricity efforts. That means embedding patient perspectives earlier and more systematically across VALUE Creation, Delivery, and Enablement, while continuing to learn from what works, adapting where we need to, and measuring the impact we deliver together.

None of this is possible without trust. I want to thank our patient partners for their openness, challenge, and collaboration, and our teams for their commitment to listening and translating insight into action. I am excited about what comes next and confident that, together, we can continue turning insight into impact - delivering better, more human healthcare for the communities we serve.

How patient involvement continues to shape our work

At Astellas, our VISION is to work on the forefront of healthcare change to turn innovative science into VALUE for patients. That means developing solutions that not only treat disease but also enhance the entire patient experience – physical, emotional, and social – so people can live better lives.

We aim to ensure that VALUE for Astellas always reflects VALUE for patient communities. We bring the patient perspective into every stage of our work, making sure patients are at the heart of how we create, deliver, and enable VALUE.

But what does creating, delivering, and enabling VALUE for patients mean?

VALUE Creation

"For people living with serious diseases, science has the potential to change everything. In VALUE Creation, we have a shared vision to better support and understand patients' needs and a focus on developing breakthrough medicines that can transform patients' lives."

Tadaaki Taniguchi,
Chief Research & Development Officer, Astellas

VALUE Delivery

"Our responsibility in VALUE Delivery is to translate innovation into customer impact to ensure that our innovative treatments reach patients in a way that is timely and represents the best treatment option for the individual patient in his or her setting. Working with patient communities helps us deliver better, faster, and with greater relevance."



Claus Zieler,
Chief Commercial & Medical Affairs Officer, Astellas

VALUE Enablement

"VALUE Enablement ensures patient perspectives are embedded in our ways of working. Astellas focuses on end-to-end support along the patient journey, fostering partnerships and leveraging insights to enhance patient-centric solutions and decision-making across the organization."



Tatjana Dragovic,
General Counsel and Chief Ethics & Compliance Officer

The examples in this report show how the patient voice continues to shape Astellas' work and increase the impact we deliver. While we can only feature some initiatives here, we deeply value every partnership and every community we work with. Each collaboration contributes to our shared goal, turning innovative science into VALUE for patients.

To all patients, caregivers, and advocacy groups, thank you for your trust and continued collaboration.

Our work in gastric cancer

Gastric cancer is often diagnosed late because early symptoms can be vague or overlooked, making timely detection and treatment a major challenge. Even after treatment, survivorship brings significant physical and emotional challenges that deeply affect quality of life. Awareness, education, and access to treatments vary globally. That's why we work with patient organizations worldwide to develop patient-centric solutions.

Our focus over the past year has been on three key priorities:

1. Raising awareness of gastric cancer symptoms to support early diagnosis
2. Improving access to biomarker testing and personalized treatment
3. Collaborating with patient communities to create resources that help people make informed decisions about managing their gastric cancer and improving quality of life

Campaign with *Vivere Senza Stomaco si Può* ODV to improve symptom awareness

In Italy we sponsored a disease awareness campaign led by *Vivere Senza Stomaco si Può* ODV to highlight the symptoms of gastric cancer and the importance of early diagnosis – this included sharing stories of courage and hope from those affected. To engage a wide audience, the campaign partnered with a well-known Italian television host and was visible in multiple places including subway stations across Milan and Rome. The campaign secured 152 pieces of media coverage, and the subway content reached 11 million people, significantly increasing awareness of gastric cancer in Italy.

The campaign reached **11 million people**

Supporting mental health

We recognize that the support we provide must address the psychological and emotional impact of gastric cancer. In the US, we are developing a mental health journal in collaboration with gastric cancer patient organizations. Launching in early 2026, it will offer practical tools for emotional wellbeing, including information, journaling prompts, exercises, and inspirational quotes.

Attendees at the Debbie's Dream Foundation patient symposium at Cornell University in New York, US.

Landmark white paper in China

In China, we partnered with several patient organizations, including the Beijing Bethune Charitable Foundation (BBCF), to advance a landmark initiative: China's first gastric cancer patient quality-of-life white paper. Guided by seven gastric cancer experts and implemented by patient communities across China, this industry-first effort focuses exclusively on the living conditions and quality of life of gastric cancer patients. Its goals include identifying key pathways for early detection and treatment, advancing the clinical translation of precision and personalized medicine, and uncovering unmet patient needs. By doing so, it aims to provide scientific evidence and practical guidance to enhance cancer prevention awareness, optimize patient education systems, and develop patient-centered strategies to improve quality of life.

Additionally, the 'Guarding the Stomach Together' program was launched by leveraging China's WeChat platform, a digital tool offering information and practical prompts to help patients navigate their treatment journey with confidence.

Margareta Haag, Chair of the Nordic Network Against Cancer, speaking at Astellas' Cancer Mission Day to discuss advancing patient-centered care.

Our work in bladder cancer

Late diagnosis remains one of the biggest challenges in bladder cancer, with many patients unaware of key symptoms. Those who are diagnosed often face health disparities, limited access to testing, and treatments that can be invasive, burdensome, and require lifelong monitoring. Addressing these issues is complex and requires listening to patient voices, learning from their experiences, and exploring approaches that meet a variety of needs.

To improve our understanding of the lived experiences of those with bladder cancer, we:

Collaborated with the World Bladder Cancer Patient Coalition (WBCPC) on a multi-country survey. It explored how people with urinary symptoms seek medical information and what influences their decisions. The 4,000 responses revealed how social and psychological factors, health literacy, and symptom misattribution shape behavior.

4,000 adults responded to a survey about urinary symptoms

Held the first urothelial carcinoma (bladder cancer) patient forum in China, with 15 late-stage caregivers and family members. In collaboration with the Fujian Province Cancer Caring Family Charity (FCCF) and Dance with Cancer, we gathered insights from the event that informed the first observation report for China on the lived experience of people with urothelial carcinoma. The report, which received 3 million views in 30 days, aimed to raise the visibility of patient organizations and improve understanding of urothelial carcinoma.

To help improve care for those living with bladder cancer, we:

Supported the Wygrajmy Zdrowie Foundation, medical associations, and clinical experts in Poland to understand existing bladder cancer treatment pathways. Based on an oncologist and urologist survey, plus insights from additional clinical experts, we helped develop a consensus report with recommendations for improving the care pathway. This report was shared at key congresses and launched at a press conference, resulting in 40 media articles.

Front cover of the Optimal Bladder Cancer Patients' Pathway report in Poland.

Worked with an oncology nurse, oncologists, and a patient advocate to host a panel discussion at the Genitourinary Cancers Annual Conference in India. Together, they gave diverse perspectives on the role of patient advocacy and how all stakeholders, including pharma, need to unite to improve quality of life for those living with bladder cancer. The event was widely covered on social media by the speakers and attendees.

Sponsored a roundtable discussion between leading oncologists, health technology assessment experts, and patient organizations during the XVI All-Russian Congress of Patients.

The panelists highlighted common challenges related to diagnosis, access to medicines, and the patient journey. Proposed solutions included enhanced diagnostics, inclusion of innovative treatments in clinical guidelines, and reshaping patient referral pathways. These proposals were consolidated into a resolution, signed by all roundtable attendees, and sent to relevant legislative and executive bodies.

Proposed solutions included enhanced **diagnostics**, **inclusion of innovative treatments in clinical guidelines**, and **reshaping patient referral pathways**

A photo taken from the Fermati al Rosso open days, a series of meetings in Italian hospitals to inform the public about bladder cancer.

Our work in prostate cancer

Limited awareness and screening, late diagnosis, stigma, communication barriers, and disparities in access to care are some of the biggest challenges impacting prostate cancer management and outcomes. This past year, our goal in partnership with patient communities has been to make prostate cancer care more accessible and compassionate. As one of the most common cancers among men, these efforts are part of a global movement to close gaps in prostate cancer care and deliver meaningful VALUE where it matters most.

PROstActivos – Proactive about prostate cancer

In Spain, we partnered with ANCAP (National Prostate Cancer Association) and GEPAC (Spanish Group for Cancer Patients) to create PROstActivos – a website featuring expert insights, patient stories, medical information, and emotional support to help people with prostate cancer make informed decisions about their care. To raise awareness of PROstActivos, we launched a media campaign reaching more than 3 million people.

PROstActivos won two national awards

A **Tu Salud 2025 Award** in the *Healthcare Digital Innovation* category

NME Awards 2025 in the *Healthcare Education Support* category

Partnering with Black Health Matters

To strengthen engagement and support for Black men affected by prostate cancer, we partnered with Black Health Matters in the US to collaborate with Alpha Phi Alpha, a historic Black fraternity representing nearly 330,000 men. At their national convention, we highlighted the urgent reality that Black men face disproportionately worse prostate cancer outcomes than White men. Building on insights from this event, we launched a Community Health Insight Panel and are developing a best practice guide to help improve outreach and care for underserved populations.

Talking about sex and intimacy

In France, we worked with leading patient organizations to create a brochure that helps men understand the impact of prostate cancer on sex and intimacy. Distributed by healthcare professionals and at Astellas events, this resource features real patient stories to break down stigma and encourage open, honest conversations to help men to maintain intimacy and live well with prostate cancer.

The front cover of the sex and intimacy brochure available in France.

Our work in acute myeloid leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer that often goes unnoticed until it's advanced, making early detection critical. That's why we're committed to raising awareness and equipping patients and caregivers with the knowledge they need to act quickly. Through collaboration and education, we aim to replace uncertainty with informed decisions. These initiatives show how encouraging early diagnosis and supporting people living with AML work hand in hand – because together, they create the greatest impact on people's lives.

AML handbook

In partnership with the New Sunshine Charity Foundation (NSCF), a leading patient organization in China, we developed an AML patient handbook for patients and caregivers. Distributed online via NSCF and through 63 major hospitals, the handbook offers medical education, mental wellbeing support, and accessible social resources.

The front cover of the AML patient handbook developed for people in China.

Stories of resilience

To increase understanding of AML, we joined forces with Unidos Pro Trasplante de Médula Ósea to support a photographic exhibition called 'Living with Hematologic Cancers: Stories of Resilience'. Displayed on a busy avenue in Mexico City, the month-long exhibition used powerful imagery to highlight the impact of AML on people's lives. These photos reflected the reality of late diagnoses, treatment side effects, shared fears, and uncertainty. The campaign was featured in 40 media articles and reached more than 350,000 people on social media.

It is estimated that more than **350,000 people** walked past the exhibition each day

A photograph from the 'Living with Hematologic Cancers: Stories of Resilience' campaign in Mexico.

Our work in women's health

Stigma, lack of education and understanding, and trivialization of menopause symptoms have been identified as key barriers to women accessing the care and support that they need during the menopause transition. Throughout 2025, we have collaborated with advocacy groups and clinicians globally, taking different approaches to address these key challenges that women face. We are proud to work with the menopause community to challenge outdated stereotypes so that women can navigate this important health transition with knowledge, confidence, and choice. Here is a snapshot of our work in 2025.

> **Menopause is a universal experience, yet too many women still move through it unseen and unsupported. Through our collaboration with Astellas, across borders and sectors, we're finally shifting the narrative from silence to solidarity, bringing patient voices to life to demand better understanding, empathy, and evidence-based care.**
>
> – Lesley Salem, Founder, Over The Bloody Moon.

The Menopause Experience & Attitudes Study

To elevate conversations, in March 2025, we launched findings from the Menopause Experience & Attitudes Study in collaboration with global menopause advocates and clinicians. The study captured experiences, attitudes, and perceptions from 13,800 men and women in Australia, Brazil, Canada, Germany, Mexico, and the US. The findings exposed structural, social, and educational gaps that make menopause an overlooked public health challenge. The study findings earned 86 media articles, nearly 2 million online impressions, and 52,000 online interactions – reaching 138 million people. These results show how this research has helped to bring menopause into the mainstream conversation, reduce taboos, and drive evidence-based health engagement and advocacy.

13,800 men and women expressed their views for the study

MenoVest™ events with Over The Bloody Moon

Hot flashes and night sweats are common menopause symptoms that are often trivialized or even joked about. To challenge this, we partnered with Over The Bloody Moon, creators of the MenoVest™, a hot flash simulator. Together, we've hosted educational events in 15 countries, engaging more than 450 healthcare professionals, colleagues, members of the public, and journalists in the experience. Our teams in Hungary and Brazil developed campaign videos showing people wearing the MenoVest™ to raise awareness of menopause, its symptoms, and their impact. In Brazil, the campaign reached more than 7 million women and earned recognition at the SABRE Awards for its contribution to raising awareness about hot flashes and night sweats.

Filming volunteers wearing the MenoVest™ for the campaign video in Hungary.

Panel discussion for women in Canada

In Canada we hosted a panel discussion in collaboration with Longwoods – a healthcare publisher that provides research and news for science, health, and policy professionals. The event, Life Beyond Stigma: Elevating the Voices of Women Experiencing Menopause, convened an esteemed panel, including a menopause care pioneer, Dr. Wendy Wolfman, a nationally recognized family physician, Dr. Sheila Wijayasinghe, and The Menopause Foundation of Canada's CEO, Janet Ko. The panel was moderated by a TV personality and menopause advocate, Melissa Grelo, to discuss recommended approaches to help ensure women are empowered to ask for and receive the support they need. The event attracted nearly 500 attendees (59 in-person, 433 virtual), including healthcare providers, public health officers, and patient advocacy groups.

The Astellas team and speakers from the panel discussion event in Canada.

Menopause workshops in local pharmacies

In Germany, we supported a series of menopause events in local pharmacies to provide free, accessible education and support for women. This initiative was especially valuable for those with limited access to women's health services, particularly in rural areas. The events offered low-threshold counseling and created a trusted space for open, informative conversations about menopause between women and healthcare professionals.

A group photo of Astellas team members and menopause experts taken at an event in Munich, which provided education around menopause symptoms and management.

A picture from a menopause awareness event - 'Let's Talk About Hot Flashes' in Bulgaria. The event helped to improve understanding about the support available to women.

Astellas is a menopause-inclusive workplace

As a global organization we are committed to breaking the stigma around menopause and fostering a culture of understanding and support.
To achieve this, we launched our global 'Pledge to Champion a Menopause-Inclusive Workplace'. In collaboration with Over The Bloody Moon, we have trained more than 600 line managers and 65 menopause ambassadors across 23 countries, equipping them to support colleagues through this transition at work. We are also partnering with organizations such as the Society for Women's Health Research in the US, with outputs from this collaboration helping to inform discussions with employer coalitions and policymakers.

Team members in Mexico at the Sin Reglas 'Menopause at Work' Summit.



A picture of the Astellas team from a menopause awareness event - 'Let's Talk About Hot Flashes' in Bulgaria.

Our work in rare diseases

Because rare diseases impact only a small number of people, they are often under-researched, poorly understood, and overlooked in public health priorities. This lack of visibility leads to limited awareness, scarce information, and fewer treatment options. Because of this, working with patients and caregivers is a critical part of scientific, clinical, and strategic decision-making.

We know creating meaningful impact is cemented in engaging early with rare disease communities to develop solutions that are truly relevant, feasible, and potentially impactful for the people who need them most.

Pompe disease

Pompe disease is a rare inherited condition that makes it hard for the body to break down glycogen, leading to muscle weakness and breathing problems over time. In late-onset Pompe disease, symptoms often include muscle cramps, difficulty walking, fatigue, and sleep-related breathing issues.

Feedback from individuals and advocacy groups has guided our approach to safety, community education around possible new therapeutic approaches, quality of life considerations, and how patients measure success in clinical trials. By listening to patient voices, we have strengthened our clinical trial program's relevance and responsiveness, and made sure this research reflects real needs and experiences – not just scientific innovation.

Our US-based gene therapy asset team at a recent team building session.

X-linked myotubular myopathy

X-linked myotubular myopathy (XLMTM) is a rare genetic condition that affects muscle strength. It happens when a change in the *MTM1* gene prevents the body from making enough of a protein needed for healthy muscles. Children with XLMTM often have severe muscle weakness, and currently there is no treatment that addresses the underlying cause.

Our work with the XLMTM community began in 2020, when Astellas acquired Audentes Therapeutics. Audentes had an ongoing clinical trial called ASPIRO. During this trial, four boys sadly passed away. Investigational research with AT132 was suspended for safety concerns and is on clinical hold. We acknowledge that, at that time, we did not communicate or engage with the community as effectively as we should have. Since then, we have been working together with XLMTM community leaders to rebuild trust and collaboration.

Today, through ongoing partnership with XLMTM community leaders and an international panel of parents (XLMTM Patient Insights Panel), our relationship and collaboration with the community has strengthened. We are working with the XLMTM Patient Insights Panel to input into interventional and observational study protocols, informed consent forms, assent forms, family trial materials, plain language summaries, publications, and a diagnosis algorithm to support earlier screening and diagnosis in Europe. We have also worked with families on educational videos to raise awareness of XLMTM and its impact. We are grateful to the XLMTM community leaders who have worked on rebuilding with us, for constructively challenging us, and for contributing their significant expertise to the work we are doing – thank you for your collaboration.

We acknowledge that, at that time, we did not communicate or engage with the community as effectively as we should have.

> **"We are grateful to Astellas for remaining committed to the XLMTM community and progressing with their next generation of gene therapy, as well as helping to further advance the understanding of this rare disease. We appreciate the efforts made to improve and strengthen patient partnerships and remain hopeful that we can work together to improve the lives of individuals and families affected by XLMTM."**
>
> – Erin Ward, President, MTM-CNM Family Connection

Though we are pleased to be advancing XLMTM research with a different investigational gene therapy, our thoughts remain with the families who lost their sons during the ASPIRO trial. We share this information in honor of their legacy as their contributions continue to guide our research efforts for people living with XLMTM and their families.

Our work in geographic atrophy and vision loss

Geographic atrophy is a progressive form of age-related macular degeneration that causes irreversible vision loss, making everyday tasks like reading, driving, and recognizing faces increasingly difficult. Beyond the physical impact, geographic atrophy often leads to emotional challenges such as anxiety, isolation, and loss of independence - all of which must be considered when evaluating the VALUE of medicines intended to treat geographic atrophy.

Our team conducted two qualitative interview studies with 26 individuals living with geographic atrophy in the US and in Europe to understand and document the path to diagnosis, symptoms experienced, health-related quality of life impacts, and coping mechanisms used to manage symptoms.

Their experiences were presented at the Association for Research in Vision and Ophthalmology Congress (ARVO) in May 2025 through a poster, plain language summary, and audio version to support accessibility.

Understanding the experiences shared by people with geographic atrophy may help eye care providers to better understand the emotional impact of vision loss, improving future interactions between themselves and their patients. In addition, these findings could aid in developing accessible educational resources on geographic atrophy, treatment options, and strategies to enhance quality of life.

"To lose my vision would be the most frightening thing that I can even think about in regard to my level of independence and being able to function in this wonderful world of ours."

– Individual with geographic atrophy, from qualitative interviews conducted in the US and Europe.



Two Astellas team members at the ARVO Congress presenting their poster on the lived experiences of people living with geographic atrophy across the US and Europe.

Over the past year, we've partnered with the Ophthalmology Global Patient Insights Panel – a group of 12 patient organization executives representing people with low vision or blindness. Their perspectives have meaningfully informed our geographic atrophy research, including feedback on clinical trial protocols and early insights on cell therapy. These contributions helped refine trial endpoints and brought forward important considerations related to randomization, long-term control group participation, and the need for mental health support for participants.

Internally, we launched an Accessibility Working Group to audit websites, contracts, and educational materials. This led to improvements such as enhanced screen reader compatibility, accessible formats, and inclusive meeting practice – benefits that extend beyond vision loss communities to anyone needing accessible health information. This work has instilled the importance of always considering visibility access among our internal teams working on patient-facing content, resulting in many ongoing changes.

Their perspectives have meaningfully informed our geographic atrophy research, including feedback on clinical trial protocols and early insights on cell therapy.

Our work in organ donation and transplantation

Organ donations continue to face a range of systemic and social barriers that contribute to the scarcity of organs. Key barriers driving this include limited public awareness, cultural and ethical concerns around organ donation, low registration rates for 'opt in' consent frameworks, challenges in implementing 'opt-out' frameworks, and logistical and legal constraints around cross-border organ sharing. Improving the transplant journey for every patient, family, and donor has been a core part of Astellas' purpose for more than three decades.

In France

Around 1,000 patients die every year while waiting for a transplant. To help address this, Astellas France worked with Greffes+ Collective Foundation, to raise awareness of organ donation and improve understanding of France's 'opt-out' law. This led to 400,000 clicks on the medical booking platform, 189 radio and internet radio spots reaching 5 million daily listeners, and 27 Astellas employees engaging with local municipalities to promote the Ambassador City initiative. Astellas France was recognized as an Organ Donation Ambassador Company as part of this initiative and has since won an award at the Health Communication Festival in Deauville for this organ donation campaign.

Team members in France proudly pictured in recognition of their Organ Donation Ambassador Company title.

In Germany

We hosted an event in Berlin with policymakers and patient organizations to talk about the biggest barriers to organ donation. This followed the World Transplant Games – an international, multi-sport event organized by the World Transplant Games Federation for organ transplant recipients and living donors. We sponsored this event, which celebrates the 'gift of life' and promotes public awareness of organ donation. Outputs from the events and many talks resulted in the Federal Council submitting draft legislation to parliament to change the law to the opt-out solution for organ donation.

Team members at the policymaker event in Germany.

Team members pictured with the mascot bear at the organ donation run in Munich.

In Spain

A new law protecting living donors has been secured in Spain after more than 10 years of advocacy from our team in Spain and patient organizations, including the National Federation of Associations ALCER (Association for the Fight Against Kidney Diseases) and the National Federation of Liver Transplant Patients (FNETH). This legislation ensures donors receive paid leave and greater financial security, setting a new global benchmark for patient-centered transplant care. Ultimately, choosing to donate your organs or tissues can represent life and hope to others. We are proud to support awareness and action when it comes to organ donation.



A picture of representatives from ALCER and FNETH taken after an event at the Spanish Congress of Deputies to discuss better protection for organ donors.

In Italy

As part of Patient Centricity (PC) Month 2025, Astellas Italy had the privilege of hearing the testimonies of Teresa Siclari, Secretary of the Regional Committee of ANED Lombardy, and Giuliana Porta, Auditor of ANED – National Association of Haemodialysis, Dialysis, and Transplant APS. Astellas Italy's long-standing relationship with ANED has helped create a deeper understanding of the experiences, challenges, and needs of people living with kidney diseases or those who have undergone an organ transplant. These moments of dialogue during PC Month underpinned the VALUE that the team in Italy strive to bring to patients.

Patient organization representatives Teresa Siclari and Giuliana Porta pictured at the PC Month speaker event in Italy.

Always striving for better

Closing remarks by Doug Noland, Global Head of Patient Partnerships



Global Head of Patient Partnerships
Doug Noland

As we conclude this year's report, we extend our deepest thanks to the Astellas teams and the patient communities who make our work possible. Your trust, insights, and collaboration continue to inspire us and shape the way we deliver our commitment to patient centricity.

We are proud of the progress made and the foundations built over the past 6 years.
Yet we know that meaningful patient engagement requires constant curiosity, flexibility, and adaptation. Our goal is not perfection, but continuous improvement.

We are committed to being an organization that learns, adapts, and evolves as community needs, regulatory requirements, and healthcare systems change – aligning our goals with those of the communities we serve, because together we can make a bigger impact.

Looking ahead, we will continue challenging ourselves to explore new approaches and refine processes, so patient perspectives are integrated earlier and more often. To ensure accountability, we will explore more robust ways to measure progress and success, helping us to learn and evolve.

Thank you for being part of this journey. By listening, learning, and collaborating, we will continue to push boundaries and create solutions that keep patients at the center of healthcare decisions.

Find out more about patient centricity at Astellas

Visit **www.astellas.com/en/about/patient-centricity** for more information about Patient Centricity at Astellas and the five teams that form our Patient Centricity Team.

- Patient Partnerships
- Patient Insights & Solutions
- Medical Intelligence & Patient Insights
- Behavioral Science Consortium
- Culture & Integration

Your opinion matters

We welcome your thoughts and feedback on what the Patient Centricity Teams have done well, and where there are areas for improvement.

Please take 5 minutes to complete our short survey **here** or use the QR code below.

Alternatively, please email us to share your feedback: **patientcentricity@astellas.com**.

astellas

PATIENTS ARE WHY™
AN ASTELLAS PATIENT CENTRICITY PROGRAM



MAT-GB-NON-2026-00106
June 2026

© 2026 Astellas Pharma Inc. or its affiliates. All trademarks are the property of their respective owners.
All photographs are shared with the consent of those featured.